The FDA is forcing Pfizer and Moderna to expand warning labels about the risks of two forms of heart damage, myocarditis and ...

Consolidation is likely to continue, with the indices attempting to defend the previous Thursday’s low in the upcoming ...

Dixon Technologies' outperform rating is sustained by BNP Paribas India, citing remarkable FY25 results and future ...

The stock's fall snapped a four-day winning streak.

Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

With that in mind, let's consider two high-yield dividend stocks worth investing in: Pfizer (NYSE: PFE) and Medical ...

Though the new FDA rules limit access to COVID-19 booster vaccines, the commitment to high-risk groups lifts Moderna, Pfizer ...

A record number of so-called reverse Yankee deals have been sold this year, an early sign of a possible lasting shift in the ...

Those two descriptions definitely apply to the healthcare sector. People need healthcare products and services regardless of ...

Pfizer shares climbed Tuesday after two punchy headlines hit the wire. FDA advisors are considering COVID-19 vaccines for ...

Pfizer share price gained 13% in the intraday trades on Tuesday post Q4 Results, dividend announcement and despite stock ...

BMO Capital analyst Evan Seigerman maintained a Buy rating on Pfizer Inc. (NYSE:PFE) and kept the price target the same at ...